Christopher U.

Christopher U. Jones, M.D ., Daniel Hunt, Ph.D., David G. McGowan, M.B., Ch.B., Mahul B. Amin, M.D., Michael P. Chetner, M.D., Deborah W. Bruner, R.N., Ph.D., Indicate H. Leibenhaut, M.D., Siraj M. Husain, M.D., Marvin Rotman, M.D., Luis Souhami, M.D., Howard M. Sandler, M.D., and William U. Shipley, M.D.: Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer In the 1980s, advances in both surgery and radiotherapy for clinically localized prostate cancer led to their acceptance as successful treatments, with considerable reductions in harmful unwanted effects as compared with earlier treatments.5 Short-term androgen-deprivation therapy may potentially mitigate these toxic effects. A Radiation Therapy Oncology Group phase 3 scientific trial, reported in 1994, showed that short-term ADT administered for 4 a few months before and during radiation therapy significantly improved local control and disease-free survival among patients with heavy stage T2c to T4 tumors.6,7 Various other trials have also proven benefits from this approach.8,9 The introduction of prostate-specific antigen testing has led to increased diagnoses of early-stage disease.1,10 Less is well known about the role of short-term ADT in men receiving radiotherapy for these cancers.